Corrections

Provider prices and care details updated

We checked current product pages and policies. Each review now distinguishes advertised minimums, recurring charges and longer commitments, and describes conflicting information where the provider's pages disagree.

• HumeCare+

  Corrected the statement that HumeCare publishes no price: its dedicated program now advertises semaglutide at $199 billed monthly, while homepage welcome-credit framing requires confirmation of the actual renewal. Removed the unconfirmed current $299 tirzepatide and oral-route claims. Added the published Alabama, Louisiana and Mississippi exclusions. Clarified that consultation costs are part of an integrated fee rather than necessarily an additional bill, device inclusion depends on the plan, and the current homepage and terms both describe a conditional ninety-day guarantee. Muscle-retention results are now identified as the company’s own reports rather than independent evidence.

• He & She MD

  Corrected the hormone-price description: estradiol patch, gel and tablet pages now specify $375 every three months, with progesterone included at no extra charge when clinically appropriate with estradiol bought through the service. Qualified injection prices because monthly plan cards conflict with legal terms describing approximately twenty-eight-to-thirty-day billing. Added conflicting shipping-policy exclusions, conditional brand access, possible separate lab costs and the unresolved allocation of injectable prescriptions between named pharmacies.

• Pepti

  Corrected the price labels to show starting-dose charges every four weeks, rather than calendar-month rates. The long review already described the 28-day billing cycle; the summary and cost-index classification now reflect it too.

• Vaylen

  Vaylen now shows a $129 monthly semaglutide option and a $996 annual plan. We removed unconfirmed brand access and clarified that its broader women’s-health service is coming soon.

• MadeMed

  MadeMed’s expanded review now distinguishes quarterly payments from two-month shipments and identifies its published clinical group and pharmacy partner. State eligibility remains conditional.

• Oak

  Oak’s current public order form shows $250 semaglutide and $300 tirzepatide one-month options, oral semaglutide and separately priced brand pens. We removed the outdated absence-of-price and absence-of-format claims.

• Alloy

  Alloy’s terms identify Curexa, BLEND and Gogo Pharmacy. We removed the statement that no pharmacy was named and retained the required $99 care fee above medication cost.

• Cora Health

  We corrected Cora’s pharmacy accreditation wording: its current FAQ describes Hallandale as PCAB-accredited and VialsRx as a licensed 503A pharmacy. It also identifies Wasef Health, PC as its clinical group.

• Live Vital

  Live Vital now publishes a 50-state general-care list and a separate 34-state testosterone footprint. The review retains the ten-week protocol arithmetic and flags an unfinished medical-disqualification refund explanation.

• Measured

  Measured’s current medication pages list compounded plans from $119/$219 with medication included and brand care from $49 with medication separate. We clarified that laboratory requirements and current state eligibility need confirmation.

• Nolu

  Nolu’s current standard rates are $199 injectable semaglutide, $279 injectable tirzepatide and $239 oral semaglutide every four weeks. The review also states the 72-hour cancellation notice requirement.

• SkinnyRx

  SkinnyRx currently labels both $99 injection offers as first-month pricing. We replaced outdated continuing-price claims with a request to confirm renewal and noted that the brand-pill cards reviewed are marked unavailable.

• Pallas Health

  Pallas now publishes $199/$299 four-week renewals after $139/$179 introductory periods, charge-on-prescription terms for current purchases and a real menopause hormone-treatment catalog. We removed the obsolete twelve-week-only billing and coming-soon hormone claims.

• WellMedr

  WellMedr, also using welludr branding, now names Logos, Emerald Compounding and Center City Pharmacy. Its policy specifies payment before clinical review, a 21-day recurring plan and pharmacy-preparation refund cutoffs.

• SnagRx

  SnagRx’s current FAQ excludes Louisiana and requires patients in Nebraska to be at least nineteen. The review now qualifies discounted-term headline prices rather than treating them as confirmed flexible monthly rates.

• Alinwell

  Alinwell’s current public pages do not establish a complete renewal quote. We removed stale introductory-price and policy assertions, retained its current 48-hour processing cutoff and distinguished women-focused marketing from comprehensive hormonal care.

• Goldspan Health

  Goldspan’s linked injectable prices are $229/$299 per 28 days. We added the unresolved difference between optional labs on the homepage and required follow-up testing on the linked product pages.

• NEUVÉ Health

  NEUVÉ now lists standard injections from $219/$349 and says treatment plans include prescribed medication, clinician review, shipping and injection supplies. Labs remain separate, and possible additional platform fees still need clarification.

• MEDGm

  MEDGm’s current public pages do not confirm a complete renewal price. We removed stale price promises and explain advance billing, the 72-hour cancellation request and named pharmacy partners.

• Collective

  Collective’s $59/$69 medication prices require a separate $199 annual membership after the 21-day trial. We clarified automatic conversion, non-refundable membership and the conditional wording of a possible technology fee.

• Rx.com

  Rx.com now advertises annual prepaid equivalents of $99/$149, with $175/$285 flexible monthly options. We corrected the state-count conflict to 47 versus 50 and removed reliance on the older no-automatic-renewal promise.

• Idgie Health

  Idgie’s current terms explicitly state there is no membership fee. We removed the old fee-ambiguity claim and show the actual prepaid totals and automatic-renewal terms.

• No BS RX

  No BS RX’s current monthly standard prices are $149 injectable semaglutide, $225 tirzepatide and $174 oral semaglutide, with separate microdose programs from $115. Its sleep diagnostic program is $396 cash rather than a $33 monthly treatment.

• Renlo Health

  Renlo’s current published rates are $149 semaglutide and $199 tirzepatide monthly. We removed the assumption of one guaranteed pharmacy and clarify that the advertised four-month guarantee has conditions.

• Science & Co

  Updated the twelve-month compounded starting prices to $59 for semaglutide and $99 for tirzepatide, retained the commitment qualification, and added the currently listed Wegovy injection and tablet routes. The hormone page reviewed is male testosterone marked coming soon, rather than an active women's HRT service.

• HealthSource

  Clarified that injection prices start at $199 and $299 every four weeks and require a selected-supply quote. Removed previously stated eight-week savings that were not confirmed in the current public price presentation.

• Try Ageless

  Replaced the older affiliate-plan pricing with a requirement for a current product-specific quote. The present catalog and tirzepatide tablet page disagree, and the review now explains the consultation fee, refund deductions and prepaid repricing.

• Prime Doctor RX

  Corrected the women's-care description: the published testosterone and enclomiphene eligibility is male. The separate weight-loss program remains relevant to eligible women, with four-week billing clearly identified.

• Effecty

  Corrected continuing compounded prices to $170 for semaglutide and $235 for tirzepatide, separated first-order discounts and longer-plan equivalents, and added the separately priced women's hormone service.

• Precision Telemed

  Separated the lower maintenance-dose prices from full treatment. Full semaglutide is $149.99 monthly; full tirzepatide is $199 initially and $249.99 thereafter. Added the current women's HRT program and its separate lab options.

• PepHaūs

  Corrected flexible tirzepatide to $239 monthly and identified the $215 headline as a six-month equivalent with $1,291 billed. Semaglutide remains a starting figure requiring confirmation of the selected commitment.

• REMEVi

  Corrected availability to forty-nine states and Washington, D.C., excluding Louisiana. Clarified four-week billing, full prepaid totals, the oral semaglutide option and included clinician-required GLP-1 labs.

• Curex

  Separated the weight-loss offer from allergy-program pricing and insurance statements. Clarified introductory amounts versus an unconfirmed product-specific renewal quote, California's oral-only restriction, and the detailed sixteen-week warranty conditions.

• Trimi

  Clarified that six-month and annual terms do not renew automatically, while monthly and quarterly plans do. Added the current prescription-issued refund cutoff and conditions on switching an existing term to later promotional pricing.

• Telos Rx

  Removed stale oral and microdose price assertions in favor of current plan-specific quotes. Clarified the plan-dependent $139 injection headline, named clinical and pharmacy partners, and conflicting statements about included lab testing.

• Mochi Health

  Corrected outdated limited-state and compounded-only descriptions. The current program describes nationwide access, approved-brand and oral options, and a menopause service. Medication starts at $60 for semaglutide or $90 for tirzepatide by dose, with membership charged separately; these are not all-dose totals.

• Breeze Meds

  Removed older intake-derived tirzepatide renewal figures that were not confirmed on current public pages. The $199 headline is for weight-loss injections generally, without a confirmed molecule, dose or supply.

• Synergy Rx

  Removed unconfirmed public semaglutide and tirzepatide prices. The current site supplies GLP-1 prices after consultation and describes conditional all-fifty-state service, named medical and pharmacy partners, and both branded and compounded routes.

• FORM (by GBY)

  Updated current standard semaglutide pricing to $99 initially and $159 thereafter, distinguished FORM3 combination pricing, and added published oral amounts. Tirzepatide FORM3 is $199 initially and $299 thereafter; membership and medication costs remain separate for branded routes.

• RX Bella

  Removed the unconfirmed current oral-route claim. The reviewed offer lists injection and lower-dose programs, with thirty-day recurring billing and separate future-renewal and initial-order cancellation rules.

• yourEra

  Its catalog now advertises $73 and $123 minimums without a complete public payment ladder. Optimum coaching, nutrition and labs are coming soon, rather than a current included benefit.

• HealthRX

  Monthly renewals are $165 for semaglutide and $214 for tirzepatide, each after a $99 first month. Current product menus list compounded injections, and the site now states 50-state service. Longer plans list fewer supply weeks than their billing terms imply.

• Found

  Current terms price the molecules separately: cash-pay semaglutide renews at $289 and tirzepatide at $359 every four weeks on flexible plans. Insurance-supported plans, first-cycle discounts and longer commitments have separate prices. Four-week billing means 13 charges in 52 weeks.

• Gala Health

  Current pages show different $179 yearly and $199 three-month offers. The review now explains those differences and the 72-hour cancellation notice. The Wegovy pill is labeled coming soon.

• Sprout Health

  Current flexible prices are $149 for semaglutide and $199 for tirzepatide every four weeks, with separate annual prepaid prices. Its terms name pharmacies and six excluded states; the current homepage does not offer a brand-name purchasing plan.

• System Labs

  The FAQ now names The Pharmacy Hub and qualified 50-state service. Cancellation instructions conflict between the landing page and FAQ, so the review no longer promises dashboard cancellation without qualification.

• Lttl

  Current monthly prices are $99 and $149, with $89 and $139 equivalents on annual prepayment. The site now names clinical reviewers and pharmacies. We removed old product-card criticisms and the unconfirmed oral GLP-1 claim.

• Strut Health

  Current semaglutide offers are $129 injectable and $99 oral. Linked tirzepatide offers advertise $149 injectable and $199 oral in the men's section; the review qualifies women's eligibility. The menopause catalog now includes a $69 compounded hormone offer.

• Direct Meds

  Current semaglutide prices are $249 sublingual and $297 injectable. We removed old unverified tirzepatide prices and added the live menopause-care service and its separate prices. Marketing and terms disagree about subscriptions and refunds.

• Bodybuilding Health+

  Current pages disagree about whether $179 and $209 are first-month or ongoing prices and publish conflicting tirzepatide bundles. We removed the old inverted-bundle conclusion and now request a complete renewal quote.

• MyDrHank

  The review now distinguishes current monthly prices from annual prepayment and no longer presents an old affiliate-only state list as current consumer coverage. Prepaid refund terms need confirmation.

• Peter MD

  Current public GLP-1 packages differ in price, supply and state exclusions. The 120 mg tirzepatide product is a $1,094 quantity-based purchase, not a fixed monthly price, and introductory pricing is qualified.

Prices and plan details corrected

We re-read each company's own pricing pages, FAQ and terms. Where a fact we published no longer matched, we corrected the review, and where a corrected fact changed a score, the score moved by our published rules.

• CoreAge Rx

  We showed $99 a month for semaglutide and $149 for tirzepatide. CoreAge's own product pages now say "Starting at $79" and "Starting at $129" a month. We also stopped saying it serves all 50 states: its FAQ says some state limits are confirmed at intake.

• Eden

  We showed $239 and $349 a month. Eden's own drug pages show $99 for semaglutide and $129 for tirzepatide at every dose. Its terms describe a separate membership, which the review now explains, and it prescribes brand-name medicines, which we had missed.

• Ro

  We said Ro's prices were not published. Ro publishes brand-name cash prices (the Wegovy pill from $149 a month, Zepbound from $299) plus a $149 monthly membership ($39 the first month). Ro sells no compounded GLP-1s.

• AgelessRx

  We showed $139 a month. That figure is a starting rate on a prepaid four-month plan, and the review now labels it that way. AgelessRx also says it serves every US state, with some treatments limited.

• Elara Health and Wellness

  Elara bills every four weeks, which is 13 charges a year, not monthly: $249 for semaglutide and $339 for tirzepatide, less on its 52-week plan. It also offers oral semaglutide, which we had listed as unavailable.

• Shed

  We showed $249 and $349 a month. Shed's own site shows $199 for semaglutide and $299 for tirzepatide month to month, and less on a 12-month plan.

• Henry Meds

  Semaglutide injections are $297 a month month to month (its dissolving tablets are $249). Tirzepatide comes only as dissolving tablets, $1,047 for three months, with no injection option.

• NiceRx

  We showed $199 and $299 a month. NiceRx charges $149 and $249 every four weeks, and it does not serve Alaska, Kansas, Mississippi or New Jersey.

• Vytora Health

  Tirzepatide is $249 a month month to month. The $199 we showed is its rate on a three-month plan.

• BetterMe Rx

  We showed $199 and $299 a month. BetterMe Rx's own site publishes no GLP-1 prices before the medical intake, and the review now says so.

• Oak

  Oak's summary quoted $200 and $250 a month. Its own order form shows $250 for semaglutide and $300 for tirzepatide, and the summary now matches.

• Gala Health

  We showed $1,299 a month for semaglutide, which is Gala's brand-name Ozempic price. Its compounded semaglutide is $199 a month on a three-month plan.

• Ondra Health

  We said Ondra offers brand-name medicines. Its FAQ says it offers two compounded GLP-1s and nothing else.

A second round of price and plan checks

We wrote full reviews of twelve more companies from their own websites, then brought each company's summary, prices and scores in line with what those pages say.

• Sesame Care

  Earlier this month we changed Sesame's prices to the drugmakers' own lists. We have changed them back to what Sesame's own pages say: the Wegovy pill is $149 a month at 1.5 and 4 mg, and the Zepbound KwikPen is $499 at 7.5 mg and $699 at 10 to 15 mg. The review tells you to check the drugmaker's current price before you fill.

• Tyde Wellness

  We showed $149 and $249 a month. Tyde charges $249 for semaglutide and $349 for tirzepatide month to month, less on 3- and 6-month plans. Its GLP-1s are injections only, and it runs a priced menopause hormone program we had not mentioned.

• Embody

  We said Embody refunds you if your medication has not been ordered. Its refund policy says all sales are final. We also said it gives no birth-control guidance (it does), that it serves 49 states (it publishes no list), and that it sells a medicated gum (its store sells injections only).

• RxSpan MD

  RxSpan MD no longer names its pharmacies or prescribing doctors, and it publishes no state list or refund policy. The review and summary now say so, and its score moved by our published rules.

• Enhance MD

  We scored Enhance MD as built for women. Its site has no PCOS, menopause or hormone care, so that part of its score now follows our rules for a general program. We also said it serves all 50 states: it is licensed in all 50 but has launched in 40 states and DC.

• Good Girl Rx

  We said Good Girl Rx runs a hormone-therapy line. Its help center lists no hormone treatments. We also said it serves all 50 states; its terms say "certain states" and give no list.

• Fresh Day Meds

  We called its lowest plans microdoses and said 23-day renewals add about 9% a year. They are ordinary starting doses, and renewing every 23 days means about 16 charges a year, roughly a third more than paying monthly.

• Mint Med

  We showed $149 and $179 a month. Mint Med's main product pages show $89 for semaglutide and $119 for tirzepatide month to month. Another of its pages lists $129 for semaglutide, and the summary now says so. Its homepage also lists its states.

• Try Invigor

  Invigor Medical now trades as Try Invigor. Its starting prices are $225 for semaglutide and $350 a month for tirzepatide (we showed $199 and $339), with no price published for higher doses. It is built around men's health, which its score now reflects.

• Hims & Hers

  We showed compounded semaglutide at $199 a month. Hims and Hers now prescribe only brand-name GLP-1s (the Wegovy pill from $149, Zepbound from $299, plus pills), with a $149 monthly membership on top, and GLP-1s are not yet offered in every state.

• Cielo

  Cielo added a 12-month plan: $84 a month for semaglutide and $119 for tirzepatide. Its sale banners and plan tables do not agree, and the review says so.

• Fitish

  We said Fitish serves all 50 states; it publishes no state list. We added its low-dose plan and its tirzepatide tablet, and its score now reflects that all sales are final.

Eight programs now link straight to the company

These companies paused the affiliate programs we used. Their reviews stay up, their buttons now go to each company's own website, and they no longer get partner placement in our lists.

• Breeze Meds
• Care Bare Rx
• Synergy Rx
• Try Ageless
• Telos Rx
• Trimi
• He & She MD
• Pallas Health

Warning-letter notices moved into place on three reviews

Three reviews mentioned an FDA warning letter only in their text. Each now shows it in the standard notice on that company's own review, and its score carries the same deduction our methodology applies to every provider with one.

ShedRx is now shown as Shed

• Shed

  The company now trades as Shed, so its review, lists and comparisons use that name. The review's web address did not change.